WO2001095906A1 - Treatment and prevention of cardiac insulin resistance associated conditions - Google Patents

Treatment and prevention of cardiac insulin resistance associated conditions Download PDF

Info

Publication number
WO2001095906A1
WO2001095906A1 PCT/GB2000/002347 GB0002347W WO0195906A1 WO 2001095906 A1 WO2001095906 A1 WO 2001095906A1 GB 0002347 W GB0002347 W GB 0002347W WO 0195906 A1 WO0195906 A1 WO 0195906A1
Authority
WO
WIPO (PCT)
Prior art keywords
insulin resistance
cardiac
heart failure
treatment
congestive heart
Prior art date
Application number
PCT/GB2000/002347
Other languages
French (fr)
Inventor
Ameet Nathwani
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2002510084A priority Critical patent/JP2004503499A/en
Priority to EP00938933A priority patent/EP1292301A1/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Priority to IL15345200A priority patent/IL153452A0/en
Priority to DZ003389A priority patent/DZ3389A1/en
Priority to CA002436116A priority patent/CA2436116A1/en
Priority to APAP/P/2002/002688A priority patent/AP2002002688A0/en
Priority to HU0301103A priority patent/HUP0301103A2/en
Priority to MXPA02012619A priority patent/MXPA02012619A/en
Priority to CNA008197679A priority patent/CN1592620A/en
Priority to PCT/GB2000/002347 priority patent/WO2001095906A1/en
Priority to BR0017254-5A priority patent/BR0017254A/en
Priority to EA200300028A priority patent/EA200300028A1/en
Priority to YU1203A priority patent/YU1203A/en
Publication of WO2001095906A1 publication Critical patent/WO2001095906A1/en
Priority to BG107384A priority patent/BG107384A/en
Priority to NO20026000A priority patent/NO20026000L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates to a novel treatment and in particular to a method for the treatment and/or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance.
  • Increases in insulin resistance represent an impairment in the normal biological response to insulin. It is usually associated with conditions such as Type 2 diabetes mellitus where the resistance is primarily manifest in skeletal muscle, adipose tissue and the liver. In certain circumstances however, insulin resistance presents in tissues and organs other than in skeletal muscle and liver and in particular can be present selectively in the heart as cardiac- insulin resistance. In diseases such as cardiac syndrome-X [a form of microvascular angina], or in patients with accelerated atherosclerosis or chronic heart-failure, the increased insulin resistance in the myocardium impairs the ability of the myocardium to rapidly and effectively utilise glucose for metabolism, and may further exacerbate the delicate metabolic balance in this critical tissue.
  • cardiac syndrome-X a form of microvascular angina
  • the increased insulin resistance in the myocardium impairs the ability of the myocardium to rapidly and effectively utilise glucose for metabolism, and may further exacerbate the delicate metabolic balance in this critical tissue.
  • EP 0306228 is 5-(4-[2-(N-methyl-N-(2- ⁇ yridyl)amino)ethoxy]benzyl)-2,4- thiazolidinedione (or 'Compound (1)0.
  • PPAR ⁇ peroxisome proliferator-activated receptor
  • USP 5521201 discloses that Compound (I) is useful in the treatment of cardiac disease especially athereosclerosis. Also WO 00/04889 discloses that Compound (I) is useful for reducing post-ischaemic injury of the heart and/or improving the functional recovery of the heart following myocardial ischaemia.
  • Compound (I) has activity in the treatment or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance. It is therefore of potential use in the treatment or prophylaxis of microvascular angina, atherosclerosis associated with insulin resistance and in the treatment of congestive heart failure, especially in delaying the progression of congestive heart failure, ameliorating or reversing reductions in cardiac muscular endurance and strength associated with congestive heart failure and ameliorating and/or reversing the cachexic phase of congestive heart failure.
  • the invention provides a method for the treatment or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance, in humans or non-human mammals, which method comprises the administration of an effective, non- toxic and pharmaceutically acceptable amount of a PPAR ⁇ agonist, such as Compound (I), or a pharmaceutically acceptable derivative thereof.
  • a PPAR ⁇ agonist such as Compound (I)
  • Particular conditions associated with cardiac insulin resistance include microvascular angina and congestive heart failure.
  • a further condition associated with cardiac insulin resistance is atherosclerosis associated with insulin resistance.
  • a suitable condition associated with cardiac insulin resistance is microvascular angina.
  • a suitable condition associated with cardiac insulin resistance is congestive heart failure.
  • the present treatment is particularly indicated to delay the progression of congestive heart failure, ameliorate and/or reverse reductions in cardiac muscular endurance and/or strength associated with congestive heart failure and ameliorate and/or reverse the cachexic phase of congestive heart failure.
  • the present treatment delays the progression of congestive heart failure.
  • the present treatment ameliorates and or reverses reductions in cardiac muscular endurance and/or strength associated with congestive heart failure.
  • the present treatment ameliorates and/or reverses the cachexic phase of congestive heart failure.
  • Suitable PPAR ⁇ agonists include thiazolidinediones, especially thiazolidine-2,4- diones, that is a compound comprising a moiety of formula (A):
  • Suitable compounds comprising a moiety of formula (a) include compounds of formula (I):
  • T represents an aryl or heterocyclyl group optionally substituted with one or more alkyl groups, aralkyl groups or heterocyclylalkyl groups, the said alkyl, aralkyl and heterocyclylalkyl groups themselves being optionally substituted.
  • the carbon atom marked with an asterisk (*) in formula (I) is a chiral carbon.
  • T represents a moiety selected from the list consisting of (a), (b), (c),
  • Thiazolidinedione PPAR ⁇ agonists may exist in one of several tautomeric forms, all of which are encompassed by the present invention as individual tautomeric forms or as mixtures thereof. Where a PPAR ⁇ agonist contains a chiral carbon, and hence exists in one or more stereoisomeric forms or where one or more geometric isomers exist, it will be appreciated that the method of the present invention encompasses all of the said forms of the PPAR ⁇ agonists whether as individual isomers or as mixtures of isomers, including racemates.
  • thiazolidinediones are those disclosed in EP 0306228 and WO94/05659. Further particular examples are the thiazolidinediones disclosed in EP0139421 and USP 5478852.
  • a preferred thiazolidinedione is Compound (I). Further particular thiazolidinediones are, (+) -5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8- tetramethyl-2H- 1 -benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(l-methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) or 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl)thiazolidine-2,4-dione (or englitazone)
  • PPAR ⁇ agonist' relates to an agonist, such as a small molecular weight agonist, of the peroxisomal proliferator-activated receptor of the gamma subtype, this nuclear receptor is a member of the ligand activated transcription factor family that include the steroid, retinoid and thyroid receptors.
  • PPAR ⁇ agonist activity may be assessed by use of the methodology disclosed by Lehmann et al : Journal of Biological Chem., 270, 12953-12956 (1995).
  • 'aryl' includes phenyl and naphthyl optionally substituted with up to five, preferably up to three, groups selected from halogen, alkyl, phenyl, alkoxy, haloalkyl, hydroxy, amino, nitro, carboxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyloxy, or alkylcarbonyl groups.
  • Suitable heterocyclyl groups are aromatic and non-aromatic heterocylic groups.
  • Suitable non-aromatic heterocylic groups include groups comprising single or fused ring heterocyclic groups comprising up to 4 hetero atoms in each ring selected from oxygen, sulphur or nitrogen, optionally fused to one or more aryl groups.
  • Suitable aromatic heterocyclyl groups include substituted or unsubstituted, single or fused ring aromatic heterocyclyl groups comprising up to 4 hetero atoms in each ring selected from oxygen, sulphur or nitrogen.
  • Favoured aromatic heterocyclyl groups include substituted or unsubstituted single ring aromatic heterocyclyl groups having 5 to 7 ring atoms, preferably 5 or 6 ring atoms.
  • the aromatic heterocyclyl groups comprise 1, 2 or 3 heteroatoms, especially 1 or 2, selected from oxygen, sulphur or nitrogen.
  • Suitable substituents for the heterocyclyl include up to 4 substituents selected from the group consisting of: alkyl, alkoxy, aryl and halogen or any two substituents on adjacent carbon atoms, together with the carbon atoms to which they are attached, may form an aryl group, preferably a benzene ring, and wherein the carbon atoms of the aryl group represented by the said two substituents may themselves be substituted or unsubstituted.
  • Tialogen' refers to fluorine, chlorine, bromine and iodine; preferably chlorine.
  • 'alkyl' and 'alkoxy' relate to groups having straight or branched carbon chains, containing up to 12 carbon atoms.
  • acyl' includes alkylcarbonyl groups.
  • Suitable alkyl groups are Cj- ⁇ alkyl groups, especially C ⁇ - alkyl groups e.g. methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl or tert-butyl groups.
  • Suitable substituents for any alkyl group include those indicated above in relation to the term "aryl”.
  • Suitable derivatives of a PPAR ⁇ agonist are pharmaceutically acceptable derivatives, for example salts and solvates.
  • Suitable derivatives of any particular PPAR ⁇ agonist include those disclosed in the above mentioned publications.
  • Suitable pharmaceutically acceptable salts include salts of salts derived from appropriate acids, such as acid addition salts, or bases.
  • Suitable pharmaceutically acceptable salts include metal salts, such as for example aluminium, alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl-b-phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine, quinine or quinoline.
  • metal salts such as for example aluminium, alkali metal salts such as lithium, sodium or potassium,
  • Suitable acid addition salts include pharmaceutically acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide and pharmaceutically acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methane-sulphonate, a-keto glutarate and a- glycerophosphate, especially the maleate salt.
  • pharmaceutically acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide
  • pharmaceutically acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methane-sulphonate, a-keto glutarate and a- glycerophosphate, especially the maleate salt.
  • Suitable pharmaceutically acceptable salts of Compound (I) are as disclosed in EP 0306228 and WO94/05659 and include maleate salts. . Suitable pharmaceutically acceptable solvates include hydrates.
  • Suitable pharmaceutically acceptable solvates of Compound (I) are as disclosed in EP 0306228 and WO94/05659 and include hydrates.
  • PPAR ⁇ agonists such as the thiazolidinediones, referred to herein are conveniently prepared according to the methods disclosed in the above mentioned patent publications in which they are disclosed:
  • Compound (I), or the tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof may be prepared using the processes described in EP 0306228 and WO94/05659.
  • salts and/or solvates of the thiazolidinediones may be prepared and isolated according to conventional procedures for example those disclosed in the, above mentioned, patent publications.
  • the present invention also provides a PPAR ⁇ agonist or a pharmaceutically acceptable derivative thereof, for use in the treatment and/or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance.
  • the present invention also provides a PPAR ⁇ agonist or a pharmaceutically acceptable derivative thereof, for use in the manufacture of a medicament for the treatment and/or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance.
  • the PPAR ⁇ agonist may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.
  • the PPAR ⁇ agonist mentioned herein is formulated and administered in accordance with the methods disclosed in the above mentioned publications, patent applications and patents. Accordingly, the present invention also provides a pharmaceutical composition for the treatment and/or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance, which composition comprises a PPAR ⁇ agonist, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier therefor.
  • the term 'pharmaceutically acceptable embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.
  • composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use.
  • compositions of the present invention will be adapted for oral administration, although compositions for administration by other routes, such as by injection and percutaneous absorption are also envisaged.
  • compositions for oral administration are unit dosage forms such as tablets and capsules.
  • Other fixed unit dosage forms, such as powders presented in sachets, may also be used.
  • the carrier may comprise a diluent, filler, disintegrant, wetting agent, lubricant, colourant, flavourant or other conventional adjuvant.
  • Typical carriers include, for example, microcrystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate, sodium lauryl sulphate or sucrose.
  • Suitable dosages of the PPAR ⁇ agonist include the known doses for these compounds as described or referred to in reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Complete Drug Reference (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) or the above mentioned publications or doses which can be determined by standard procedures.
  • Suitable dosages of the Compound (I) include those disclosed in EP 0306228 and WO94/05659 and 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg of Compound (I). .
  • Particular dosages of Compound (I) are 2mg, 4mg and 8mg.
  • Particular dosages of troglitazone include from 100 to 800mg such as 200, 400, 600 or 800mg.
  • Particular dosages of pioglitazone include from 5 to 50mg, including 10 to 40mg, such as 15, 20, 30 or 40 mg of pioglitazone.
  • the composition of the invention may be administered from 1 to 6 times a day, but most preferably 1 or 2 times per day.
  • composition of the invention may be administered from 1 to 6 times a day, but most preferably 1 or 2 times per day.
  • the solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
  • Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats
  • emulsifying agents for example lecithin, sorbitan monooleate, or
  • fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
  • the compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • Compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending upon the method of administration.
  • compositions may, if desired, be in the form of a pack accompanied by written or printed instructions for use.
  • the compositions are formulated according to conventional methods, such as those disclosed in standard reference texts, for example the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Complete Drug Reference (London, The Pharmaceutical Press) and Harry's Cosmeticology (Leonard Hill Books).
  • the activity of compounds in the treatment of the present invention can be determined using known methodology, for example by use of procedures disclosed by Eckel J, Asskamp,B, Reinauer, H (1991) Endocrinology 129, 345-352 Induction of insulin resistance in primary cultured adult cardiomyocytes. No adverse toxicological effects are expected for the compositions or methods of the invention in the above mentioned dosage ranges.

Abstract

A method for the treatment or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance, in humans or non-human mammals, which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of PPARy agonist, such as Compound (I), or a pharmaceutically acceptable derivative thereof. Conditions associated with cardiac insulin resistance are: microvascular angina, atherosclerosis and congestive heart failure. Compounds include rosiglitazone, troglitazone, englitazone and pioglitazone.

Description

TREATMENT AND PREVENTION OF CARDIAC INSULIN RESISTANCE ASSOCIATED CONDITIONS
This invention relates to a novel treatment and in particular to a method for the treatment and/or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance.
Increases in insulin resistance represent an impairment in the normal biological response to insulin. It is usually associated with conditions such as Type 2 diabetes mellitus where the resistance is primarily manifest in skeletal muscle, adipose tissue and the liver. In certain circumstances however, insulin resistance presents in tissues and organs other than in skeletal muscle and liver and in particular can be present selectively in the heart as cardiac- insulin resistance. In diseases such as cardiac syndrome-X [a form of microvascular angina], or in patients with accelerated atherosclerosis or chronic heart-failure, the increased insulin resistance in the myocardium impairs the ability of the myocardium to rapidly and effectively utilise glucose for metabolism, and may further exacerbate the delicate metabolic balance in this critical tissue. Treatment of cardiac-insulin resistance would be expected to alleviate this metabolic stress and improve the efficiency of glucose uptake, and hence oxidative metabolism of cardiac muscle. Where cardiac muscle is ischaemic and susceptible to hypoxic damage, it is believed that improving the metabolic stress of insulin resistance, will help prevent ischaemic damage to the myocardium. European Patent Application, Publication Number 0306228 discloses certain thiazolidinedione derivatives which are disclosed inter alia as having hypoglycaemic and hypolipidaemic activity and activity in treating certain eating disorders. The compound of example 30 of EP 0306228 is 5-(4-[2-(N-methyl-N-(2-ρyridyl)amino)ethoxy]benzyl)-2,4- thiazolidinedione (or 'Compound (1)0. European Patent Applications, Publication Numbers: 0306228, 0008203, 0139421,
0032128, 0428312, 0489663, 0155845, 0257781, 0208420, 0177353, 0319189, 0332331, 0332332, 0528734, 0508740; International Patent Application, Publication Numbers 92/18501, 93/02079, 93/22445 and United States Patent Numbers 5104888 and 5478852, also disclose certain thiazolidinedione derivatives which are stated to have hypoglycaemic and hypolipidaemic activity.
It is known that the γ-isoform of peroxisome proliferator-activated receptor (herein after PPARγ) is member of a nuclear receptor superfamily that includes receptors for the steroid, thyroid and retinoid hormones( Evans, Science 240, 889-895, (1'988)). It is also known from Chawla et al that PPARγ is expressed early during the differentiation of adipocytes (Endocrinology 135,798-800, 1994). It is known from J. Biol. Chem., 270,12963-12966 that thiazolidinediones such as Compound (I) are PPARγ agonists.
USP 5521201 discloses that Compound (I) is useful in the treatment of cardiac disease especially athereosclerosis. Also WO 00/04889 discloses that Compound (I) is useful for reducing post-ischaemic injury of the heart and/or improving the functional recovery of the heart following myocardial ischaemia.
It is now considered that Compound (I) has activity in the treatment or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance. It is therefore of potential use in the treatment or prophylaxis of microvascular angina, atherosclerosis associated with insulin resistance and in the treatment of congestive heart failure, especially in delaying the progression of congestive heart failure, ameliorating or reversing reductions in cardiac muscular endurance and strength associated with congestive heart failure and ameliorating and/or reversing the cachexic phase of congestive heart failure.
Accordingly, the invention provides a method for the treatment or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance, in humans or non-human mammals, which method comprises the administration of an effective, non- toxic and pharmaceutically acceptable amount of a PPARγ agonist, such as Compound (I), or a pharmaceutically acceptable derivative thereof.
Particular conditions associated with cardiac insulin resistance include microvascular angina and congestive heart failure. A further condition associated with cardiac insulin resistance is atherosclerosis associated with insulin resistance.
A suitable condition associated with cardiac insulin resistance is microvascular angina. A suitable condition associated with cardiac insulin resistance is congestive heart failure. In the treatment or prophylaxis of congestive heart failure, the present treatment is particularly indicated to delay the progression of congestive heart failure, ameliorate and/or reverse reductions in cardiac muscular endurance and/or strength associated with congestive heart failure and ameliorate and/or reverse the cachexic phase of congestive heart failure.
Suitably, the present treatment delays the progression of congestive heart failure. Suitably, the present treatment ameliorates and or reverses reductions in cardiac muscular endurance and/or strength associated with congestive heart failure. Suitably, the present treatment ameliorates and/or reverses the cachexic phase of congestive heart failure.
Suitable PPARγ agonists include thiazolidinediones, especially thiazolidine-2,4- diones, that is a compound comprising a moiety of formula (A):
Figure imgf000004_0001
Suitable compounds comprising a moiety of formula (a) include compounds of formula (I):
Figure imgf000004_0002
(i)
or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein T represents an aryl or heterocyclyl group optionally substituted with one or more alkyl groups, aralkyl groups or heterocyclylalkyl groups, the said alkyl, aralkyl and heterocyclylalkyl groups themselves being optionally substituted.
Suitably, the carbon atom marked with an asterisk (*) in formula (I) is a chiral carbon. In particular T represents a moiety selected from the list consisting of (a), (b), (c),
(d), (e), (f), (g), (h) and (i):
Figure imgf000004_0003
(a) (b)
Figure imgf000005_0001
(C) (
Figure imgf000005_0002
(e) (f)
Figure imgf000005_0003
(g) (h), and
Figure imgf000005_0004
In particular should be mentioned the moieties of formula (a), (b), (c), (d) and (e). Also included in the treatment of the invention are the PPARγ agonists disclosed in European Patent Applications, Publication Numbers: 0306228, 0008203, 0139421, 0032128, 0428312, 0489663, 0155845, 0257781, 0208420, 0177353, 0319189, 0332331, 0332332, 0528734 and 0508740, International Patent Application, Publication Numbers 92/18501, 93/02079, 93/22445 and United States Patent Numbers 5104888 and 5478852, especially the specific example thereof. The contents of these publications are included herein by reference. Thiazolidinedione PPARγ agonists may exist in one of several tautomeric forms, all of which are encompassed by the present invention as individual tautomeric forms or as mixtures thereof. Where a PPARγ agonist contains a chiral carbon, and hence exists in one or more stereoisomeric forms or where one or more geometric isomers exist, it will be appreciated that the method of the present invention encompasses all of the said forms of the PPARγ agonists whether as individual isomers or as mixtures of isomers, including racemates.
Particular examples of thiazolidinediones are those disclosed in EP 0306228 and WO94/05659. Further particular examples are the thiazolidinediones disclosed in EP0139421 and USP 5478852.
A preferred thiazolidinedione is Compound (I). Further particular thiazolidinediones are, (+) -5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8- tetramethyl-2H- 1 -benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(l-methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) or 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl)thiazolidine-2,4-dione (or englitazone)
When used herein the term PPARγ agonist' relates to an agonist, such as a small molecular weight agonist, of the peroxisomal proliferator-activated receptor of the gamma subtype, this nuclear receptor is a member of the ligand activated transcription factor family that include the steroid, retinoid and thyroid receptors.
PPARγ agonist activity may be assessed by use of the methodology disclosed by Lehmann et al : Journal of Biological Chem., 270, 12953-12956 (1995).
When used herein the term 'aryl' includes phenyl and naphthyl optionally substituted with up to five, preferably up to three, groups selected from halogen, alkyl, phenyl, alkoxy, haloalkyl, hydroxy, amino, nitro, carboxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyloxy, or alkylcarbonyl groups.
Suitable heterocyclyl groups are aromatic and non-aromatic heterocylic groups. Suitable non-aromatic heterocylic groups include groups comprising single or fused ring heterocyclic groups comprising up to 4 hetero atoms in each ring selected from oxygen, sulphur or nitrogen, optionally fused to one or more aryl groups.
Suitable aromatic heterocyclyl groups include substituted or unsubstituted, single or fused ring aromatic heterocyclyl groups comprising up to 4 hetero atoms in each ring selected from oxygen, sulphur or nitrogen. Favoured aromatic heterocyclyl groups include substituted or unsubstituted single ring aromatic heterocyclyl groups having 5 to 7 ring atoms, preferably 5 or 6 ring atoms.
In particular, the aromatic heterocyclyl groups comprise 1, 2 or 3 heteroatoms, especially 1 or 2, selected from oxygen, sulphur or nitrogen. Suitable substituents for the heterocyclyl include up to 4 substituents selected from the group consisting of: alkyl, alkoxy, aryl and halogen or any two substituents on adjacent carbon atoms, together with the carbon atoms to which they are attached, may form an aryl group, preferably a benzene ring, and wherein the carbon atoms of the aryl group represented by the said two substituents may themselves be substituted or unsubstituted. It will be appreciated that where the above mentioned definitions of 'aryl',
'heterocyclyl' and the substituents thereof differ from those in the above mentioned patent publications with respect to the particular compounds disclosed therein, that the definitions in the said publications prevail.
When used herein the term Tialogen' refers to fluorine, chlorine, bromine and iodine; preferably chlorine.
When used herein the terms 'alkyl' and 'alkoxy' relate to groups having straight or branched carbon chains, containing up to 12 carbon atoms.
When used herein the term 'acyl' includes alkylcarbonyl groups.
Suitable alkyl groups are Cj-^ alkyl groups, especially C\- alkyl groups e.g. methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl or tert-butyl groups.
Suitable substituents for any alkyl group include those indicated above in relation to the term "aryl".
Suitable derivatives of a PPARγ agonist are pharmaceutically acceptable derivatives, for example salts and solvates. Suitable derivatives of any particular PPARγ agonist include those disclosed in the above mentioned publications.
Suitable pharmaceutically acceptable salts include salts of salts derived from appropriate acids, such as acid addition salts, or bases.
Suitable pharmaceutically acceptable salts include metal salts, such as for example aluminium, alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl-b-phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine, quinine or quinoline.
Suitable acid addition salts include pharmaceutically acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide and pharmaceutically acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methane-sulphonate, a-keto glutarate and a- glycerophosphate, especially the maleate salt.
Suitable pharmaceutically acceptable salts of Compound (I) are as disclosed in EP 0306228 and WO94/05659 and include maleate salts. . Suitable pharmaceutically acceptable solvates include hydrates.
Suitable pharmaceutically acceptable solvates of Compound (I) are as disclosed in EP 0306228 and WO94/05659 and include hydrates.
The PPARγ agonists, such as the thiazolidinediones, referred to herein are conveniently prepared according to the methods disclosed in the above mentioned patent publications in which they are disclosed: Thus Compound (I), or the tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, may be prepared using the processes described in EP 0306228 and WO94/05659.
The salts and/or solvates of the thiazolidinediones may be prepared and isolated according to conventional procedures for example those disclosed in the, above mentioned, patent publications.
The present invention also provides a PPARγ agonist or a pharmaceutically acceptable derivative thereof, for use in the treatment and/or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance. The present invention also provides a PPARγ agonist or a pharmaceutically acceptable derivative thereof, for use in the manufacture of a medicament for the treatment and/or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance.
In the above mentioned method the PPARγ agonist, may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.
In the treatment of the invention, the PPARγ agonist mentioned herein is formulated and administered in accordance with the methods disclosed in the above mentioned publications, patent applications and patents. Accordingly, the present invention also provides a pharmaceutical composition for the treatment and/or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance, which composition comprises a PPARγ agonist, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier therefor.
As used herein the term 'pharmaceutically acceptable' embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.
The composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use.
Usually the pharmaceutical compositions of the present invention will be adapted for oral administration, although compositions for administration by other routes, such as by injection and percutaneous absorption are also envisaged.
Particularly suitable compositions for oral administration are unit dosage forms such as tablets and capsules. Other fixed unit dosage forms, such as powders presented in sachets, may also be used.
In accordance with conventional pharmaceutical practice the carrier may comprise a diluent, filler, disintegrant, wetting agent, lubricant, colourant, flavourant or other conventional adjuvant. Typical carriers include, for example, microcrystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate, sodium lauryl sulphate or sucrose.
Suitable dosages of the PPARγ agonist include the known doses for these compounds as described or referred to in reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Complete Drug Reference (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) or the above mentioned publications or doses which can be determined by standard procedures.
Suitable dosages of the Compound (I) include those disclosed in EP 0306228 and WO94/05659 and 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg of Compound (I). . Particular dosages of Compound (I) are 2mg, 4mg and 8mg. Particular dosages of troglitazone include from 100 to 800mg such as 200, 400, 600 or 800mg.
Particular dosages of pioglitazone include from 5 to 50mg, including 10 to 40mg, such as 15, 20, 30 or 40 mg of pioglitazone. The composition of the invention may be administered from 1 to 6 times a day, but most preferably 1 or 2 times per day.
The composition of the invention may be administered from 1 to 6 times a day, but most preferably 1 or 2 times per day. The solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents. For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
Compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending upon the method of administration.
Compositions may, if desired, be in the form of a pack accompanied by written or printed instructions for use. The compositions are formulated according to conventional methods, such as those disclosed in standard reference texts, for example the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Complete Drug Reference (London, The Pharmaceutical Press) and Harry's Cosmeticology (Leonard Hill Books).
The activity of compounds in the treatment of the present invention can be determined using known methodology, for example by use of procedures disclosed by Eckel J, Asskamp,B, Reinauer, H (1991) Endocrinology 129, 345-352 Induction of insulin resistance in primary cultured adult cardiomyocytes. No adverse toxicological effects are expected for the compositions or methods of the invention in the above mentioned dosage ranges.

Claims

Claims:
1. A method for the treatment or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance, in humans or non-human mammals, which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of a PPARγ agonist, such as Compound (I), or a pharmaceutically acceptable derivative thereof.
2. A method according to claim 1, wherein a condition associated with cardiac insulin resistance is selected from: microvascular angina, atherosclerosis associated with insulin resistance and congestive heart failure.
3. A method according to claim 1, wherein in the treatment of congestive heart failure there is provided: a delay in the progression of congestive heart failure; an amelioration and/or reversal of reductions in cardiac muscular endurance and/or strength associated with congestive heart failure; or an amelioration and/or reversal of the cachexic phase of congestive heart failure.
4. A method according to claim 1, wherein the PPAR agonist is a thiazolidinedione.
5. A method according to claim 4, wherein the PPAR agonist is selected from the list consisting of: Compound (I), (+) -5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-l- benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(l- methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[(2-benzyl-2,3- dihydrobenzopyran)-5-ylmethyl)thiazolidine-2,4-dione (or englitazone), and 5-[4-[2-(5- ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone).
6. A method according to claim 4, wherein the PPAR agonist is Compound (I).
7. A method according to claim 4, wherein the PPAR agonist is 5-[4-[2-(5-ethylpyridin-
2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone).
PCT/GB2000/002347 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions WO2001095906A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CNA008197679A CN1592620A (en) 2000-06-16 2000-06-16 Treating and preventing method of disease relative to cardiac insulin resistance
MXPA02012619A MXPA02012619A (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions.
IL15345200A IL153452A0 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions
EP00938933A EP1292301A1 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions
CA002436116A CA2436116A1 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions
APAP/P/2002/002688A AP2002002688A0 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated associated conditions.
PCT/GB2000/002347 WO2001095906A1 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions
JP2002510084A JP2004503499A (en) 2000-06-16 2000-06-16 Treatment and prevention of symptoms associated with cardiac insulin resistance
DZ003389A DZ3389A1 (en) 2000-06-16 2000-06-16 TREATMENT AND PREVENTION OF ASSOCIATED CONDITIONS OF CARDIAC INSULIN RESISTANCE
HU0301103A HUP0301103A2 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions
BR0017254-5A BR0017254A (en) 2000-06-16 2000-06-16 Treatment and prevention of conditions associated with cardiac insulin resistance
EA200300028A EA200300028A1 (en) 2000-06-16 2000-06-16 TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH HEART INSULIN RESISTANCE
YU1203A YU1203A (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions
BG107384A BG107384A (en) 2000-06-16 2002-12-12 THE USE OF PPARgamma AGONIST FOR PRODUCING OF MEDICAMENT FOR THE TREATMENT AND PROPHYLAXY OF CONDITIONS RELATED TO CARDIAC INSULIN RESISTANCE
NO20026000A NO20026000L (en) 2000-06-16 2002-12-13 Treatment and prevention of heart disease associated with insulin resistance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/002347 WO2001095906A1 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions

Publications (1)

Publication Number Publication Date
WO2001095906A1 true WO2001095906A1 (en) 2001-12-20

Family

ID=9884792

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002347 WO2001095906A1 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions

Country Status (15)

Country Link
EP (1) EP1292301A1 (en)
JP (1) JP2004503499A (en)
CN (1) CN1592620A (en)
AP (1) AP2002002688A0 (en)
BG (1) BG107384A (en)
BR (1) BR0017254A (en)
CA (1) CA2436116A1 (en)
DZ (1) DZ3389A1 (en)
EA (1) EA200300028A1 (en)
HU (1) HUP0301103A2 (en)
IL (1) IL153452A0 (en)
MX (1) MXPA02012619A (en)
NO (1) NO20026000L (en)
WO (1) WO2001095906A1 (en)
YU (1) YU1203A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770648B2 (en) 1999-06-30 2004-08-03 Tularik Inc. Compounds for the modulation of PPARγ activity

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005659A1 (en) * 1992-09-05 1994-03-17 Smithkline Beecham Plc Substituted thiazolidinedione derivatives
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
WO2000004889A1 (en) * 1998-07-21 2000-02-03 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005659A1 (en) * 1992-09-05 1994-03-17 Smithkline Beecham Plc Substituted thiazolidinedione derivatives
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
WO2000004889A1 (en) * 1998-07-21 2000-02-03 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF MEDICINE, vol. 105, no. 1 PART A, 6 July 1998 (1998-07-06), pages 4S - 14S, ISSN: 0002-9343 *
BAEHR M ET AL: "ACUTE AND CHRONIC EFFECTS OF TROGLITAZONE (CS-045) ON ISOLATED RAT VENTRICULAR CARDIOMYOCYTES", DIABETOLOGIA, BERLIN, DE, vol. 39, July 1996 (1996-07-01), pages 766 - 774, XP000856911, ISSN: 0012-186X *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, GHAZZI MAHMOUD N ET AL: "Cardiac and glycemic benefits of troglitazone treatment in NIDDM.", XP002178559, Database accession no. PREV199799461185 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 6 July 1998 (1998-07-06), HSUEH WILLA A ET AL: "Cardiovascular risk continuum: Implications of insulin resistance and diabetes.", XP002178558, Database accession no. PREV199800429872 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 1999 (1999-03-01), SHIMOYAMA MASAKI ET AL: "Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts.", XP002178557, Database accession no. PREV199900153193 *
DIABETES, vol. 46, no. 3, 1997, pages 433 - 439, ISSN: 0012-1797 *
DIABETES, vol. 48, no. 3, March 1999 (1999-03-01), pages 609 - 615, ISSN: 0012-1797 *
DOMINGUEZ LIGIA J ET AL: "Troglitazone prevents abnormalities in myocyte relaxation in an in vitro model of diabetic cardiomyopathy.", HYPERTENSION (DALLAS), vol. 28, no. 3, 1996, 50th Annual Conference and Scientific Sessions of the Council for High Blood Pressure Research;Chicago, Illinois, USA; September 17-20, 1996, pages 541, XP001028260, ISSN: 0194-911X *
GINSBERG H. ET AL: "A review of metabolic and cardiovascular effects of oral antidiabetic agents: Beyond glucose-level lowering.", JOURNAL OF CARDIOVASCULAR RISK, (1999) 6/5 (337-346)., XP001028568 *
HENRY R R: "TYPE 2 DIABETES CARE: THE ROLE OF INSULIN-SENSITIZING AGENTS AND PRACTICAL IMPLICATIONS FOR CARDIOVASCULAR DISEASE PREVENTION", AMERICAN JOURNAL OF MEDICINE, XX, XX, vol. 105, no. 1A, 6 July 1998 (1998-07-06), pages 20S - 26S, XP000877433, ISSN: 0002-9343 *
JHA R J: "THIAZOLIDINEDIONES - THE NEW INSULIN ENHANCERS", CLINICAL AND EXPERIMENTAL HYPERTENSION, MARCEL DEKKER, NEW YORK, NY, US, vol. 21, no. 1/2, January 1999 (1999-01-01), pages 157 - 166, XP000985778, ISSN: 1064-1963 *
KUEHNLE H F: "NEW THERAPEUTIC AGENTS FOR THE TREATMENT OF NIDDM", EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY AND DIABETES, JOHANN AMBROSIUS BARTH, DE, vol. 104, no. 2, 1996, pages 93 - 101, XP000605828, ISSN: 0947-7349 *
LENHARD, J. M. ET AL: "The RXR agonist LG100268 causes hepatomegaly, improves glycemic control, and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction", DIABETOLOGIA ( 1999 ), 42(5), 545-554, XP000985788 *
MURAKAMI T ET AL: "Beneficial effects of troglitazone in vasospastic angina pectoris with diabetes mellitus.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 31, no. 2 SUPPL. A, February 1998 (1998-02-01), 47th Annual Scientific Session of the American College of Cardiology;Atlanta, Georgia, USA; March 29-April 1, 1998, pages 411A, XP001028258, ISSN: 0735-1097 *
O'KEEFE J H ET AL: "IMPROVING THE ADVERSE CARDIOVASCULAR PROGNOSIS OF TYPE 2 DIABETES", MAYO CLINIC PROCEEDINGS, MAYO MEDICAL VENTURES, ROCHESTER, MN, US, vol. 74, no. 2, February 1999 (1999-02-01), pages 171 - 180, XP000856581, ISSN: 0025-6196 *
REN JUN ET AL: "Troglitazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes.", DIABETES, vol. 45, no. 12, 1996, pages 1822 - 1825, XP001028259, ISSN: 0012-1797 *
SHIMABUKURO M ET AL: "CARDIOPROTECTIVE EFFECTS OF TROGLITAZONE IN STREPTOZOTOCIN-INDUCED DIABETIC RATS", METABOLISM, CLINICAL AND EXPERIMENTAL, W.B. SAUNDERS CO., PHILADELPHIA, PA, US, vol. 45, no. 9, September 1996 (1996-09-01), pages 1168 - 1173, XP000856580, ISSN: 0026-0495 *
SUBRAMANIAM S.: "The emerging role of thiazolidinediones in the treatment of diabetes - mellitus and related disorders.", CLINICAL AND EXPERIMENTAL HYPERTENSION, (1999) 21/1-2 (121-136)., XP001028567 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770648B2 (en) 1999-06-30 2004-08-03 Tularik Inc. Compounds for the modulation of PPARγ activity
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US7968567B2 (en) 1999-06-30 2011-06-28 Amgen Inc. Compounds for the modulation of PPARγ activity

Also Published As

Publication number Publication date
YU1203A (en) 2006-05-25
BG107384A (en) 2003-09-30
EP1292301A1 (en) 2003-03-19
BR0017254A (en) 2004-01-06
JP2004503499A (en) 2004-02-05
IL153452A0 (en) 2003-07-06
CN1592620A (en) 2005-03-09
HUP0301103A2 (en) 2003-08-28
MXPA02012619A (en) 2003-04-10
AP2002002688A0 (en) 2002-12-31
EA200300028A1 (en) 2003-04-24
DZ3389A1 (en) 2001-12-20
CA2436116A1 (en) 2001-12-20
NO20026000D0 (en) 2002-12-13
NO20026000L (en) 2003-02-11

Similar Documents

Publication Publication Date Title
US20070238757A1 (en) Novel treatment
EP1593379A2 (en) Uses of PPAR-gamma agonists in neutrophil-induced diseases
WO2000076488A2 (en) Use of a ppar agonist for treating type 1 diabetes
US20040034067A1 (en) Novel method of treatment
WO2001095906A1 (en) Treatment and prevention of cardiac insulin resistance associated conditions
AU2000254153A1 (en) Treatment and prevention of cardiac insulin resistance associated conditions
ZA200300283B (en) Treatment and prevention of cardiac insulin resistance associated conditions.
OA12831A (en) Treatment and prevention of cardiac insulin resistance associated conditions.
KR20030019434A (en) Treatment and Prevention of Cardiac Insulin Resistance Associated Conditions
CZ20024067A3 (en) Medicament for treating or prophylaxis of heart resistance to insulin
US20040266833A1 (en) Novel use of certain insulin sensitizers or ppar-gamma agonists
AU1719600A (en) Novel method of treatment
AU781742B2 (en) Novel method of treatment
KR20010024482A (en) Use of Thiazolidinediones for the Treatment of Hyperglycaemia
KR20010024481A (en) Use of Thiazolidinediones for the Treatment of Hyperglycaemia
CZ7799A3 (en) Pharmaceutical preparation against leptin resistance
AU4586902A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
AU2005200702A1 (en) Novel method of treatment
MXPA00003633A (en) Use of thiazolidinediones for the treatment of hyperglycaemia

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-12/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2000 107384

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20020993A

Country of ref document: HR

Ref document number: PV2002-4067

Country of ref document: CZ

Ref document number: 2000254153

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 153452

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2002 510084

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 17842002

Country of ref document: SK

Ref document number: PA/a/2002/012619

Country of ref document: MX

Ref document number: 1020027017145

Country of ref document: KR

Ref document number: 02113554

Country of ref document: CO

Ref document number: 1200201152

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2436116

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 523392

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000938933

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003/00283

Country of ref document: ZA

Ref document number: 200300283

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: DZP2003000015

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 200300028

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 008197679

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027017145

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000938933

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-4067

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020027017145

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2000938933

Country of ref document: EP